Ventricular tachycardia remains one of the most challenging and underserved areas in cardiac care, with physicians lacking adequate tools for effective treatment. Field Medical, a clinical-stage company developing pulsed field ablation technology, recently announced the close of a $35 million Series B financing round to advance its FieldForce™ Ablation System toward pivotal trials.
Key Points
- The oversubscribed Series B round was co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. This brings Field Medical’s total funding to $75 million since its founding in 2022.
- The FieldForce™ Ablation System uses pulsed field ablation (PFA) technology designed for transmural lesion creation in ventricular tachycardia treatment. The system uses proprietary FieldBending™ technology to shape the pulsed electric fields delivered through its catheter design.
- Funding will support initiation of the company’s pivotal VERITAS trial and expand clinical and regulatory capabilities. The raise was partly driven by pilot data presented at the 2025 Heart Rhythm Society meeting.
- The company received FDA Breakthrough Device Designation in 2024 and was selected for the FDA’s TAP Pilot Program for its VT indication. The FieldForce™ Ablation System remains an investigational device limited by federal law to investigational use.
- Field Medical updated its board of directors, with Mark Wisniewski (CFO of Enterra Medical) named chairperson. The board includes founder/CEO Steven Mickelsen, MD; Marlou Janssen (former Biotronik U.S. President); Alexei Mlodinow, MD, MBA; and Ben Cannon (Founding Partner, Cue Growth).
This funding positions Field Medical to advance clinical development of a PFA system specifically designed for ventricular tachycardia, addressing a significant gap in current treatment options for high-risk cardiac patients.
The Data
- Field Medical has raised $75 million in total funding to date, with the current Series B round contributing $35 million.
- The company was founded in 2022 and received FDA Breakthrough Device Designation in 2024.
- The company did not disclose timeline details for the planned VERITAS pivotal trial.
Industry Context
Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need.
Steven Mickelsen, MD, founder and CEO of Field Medical
Field Medical is positioning its FieldForce™ system as a next-generation approach to cardiac ablation, specifically targeting the ventricular tachycardia market. The company’s technology uses pulsed field ablation, an emerging modality in cardiac electrophysiology that aims to create targeted tissue ablation. According to the company, VT represents an underserved market segment that mirrors the early development of the atrial fibrillation treatment market.
The FieldForce™ Ablation System incorporates what Field Medical describes as FieldBending™ energy technology combined with specialized catheter design. The company’s founder, Dr. Steven Mickelsen, is an inventor of previous PFA technologies including FARAPULSE. With new funding, FDA Breakthrough Device Designation, and selection for the TAP Pilot Program, Field Medical is advancing toward clinical trials.
